Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Context: Standard glucocorticoid therapy in congenital adrenal hyperplasia (CAH) regularly fails to control androgen excess, causing glucocorticoid overexposure and poor health outcomes. Objective: We investigated whether modified-release hydrocortisone (MR-HC), which mimics physiologic cortisol secretion, could improve disease control. Methods: A 6-month, randomized, phase 3 study was conducted of MR-HC vs standard glucocorticoid, followed by a single-arm MR-HC extension study. Primary outcomes were change in 24-hour SD score (SDS) of androgen precursor 17-hydroxyprogesterone (17OHP) for phase 3, and efficacy, safety and tolerability of MR-HC for the extension study. Results: The phase 3 study recruited 122 adult CAH patients. Although the study failed its primary outcome at 6 months, there was evidence of better biochemical control on MR-HC, with lower 17OHP SDS at 4 (P = .007) and 12 (P = .019) weeks, and between 07:00h to 15:00h (P = .044) at 6 months. The percentage of patients with controlled 09:00h serum 17OHP (< 1200 ng/dL) was 52% at baseline, at 6 months 91% for MR-HC and 71% for standard therapy (P = .002), and 80% for MR-HC at 18 months’ extension. The median daily hydrocortisone dose was 25 mg at baseline, at 6 months 31 mg for standard therapy, and 30 mg for MR-HC, and after 18 months 20 mg MR-HC. Three adrenal crises occurred in phase 3, none on MR-HC and 4 in the extension study. MR-HC resulted in patient-reported benefit including menses restoration in 8 patients (1 on standard therapy), and 3 patient and 4 partner pregnancies (none on standard therapy). Conclusion: MR-HC improved biochemical disease control in adults with reduction in steroid dose over time and patient-reported benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a recent clinical trial comparing immediate-release and MR-HC in patients with CAH, both groups were able to achieve better 24-hour 17-OHP levels at 24 weeks compared to baseline, thus failing to prove their primary outcome.”
From Hypoglycaemia in adrenal insufficiency (2023) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, an extension of this clinical trial showed an overall improvement in disease control in the MR-HC group due to lower 17-OHP and androstenedione levels at multiple points throughout the day, with a significant reduction in 17-OHP variability.”
From Hypoglycaemia in adrenal insufficiency (2023) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, an extension of this clinical trial showed an overall improvement in disease control in the MR-HC group due to lower 17-OHP and androstenedione levels at multiple points throughout the day, with a significant reduction in 17-OHP variability.”
From Hypoglycaemia in adrenal insufficiency (2023) · cites this paper as [60]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Dose reduction was also achievable in the MR-HC group whilst maintaining good disease control (60).”
From Hypoglycaemia in adrenal insufficiency (2023) · cites this paper as [60]
The cited source says what the claim attributes to it.
In the citing paper
“In a recent clinical trial comparing immediate-release and MR-HC in patients with CAH, both groups were able to achieve better 24-hour 17-OHP levels at 24 weeks compared to baseline, thus failing to prove their primary outcome.”
From Hypoglycaemia in adrenal insufficiency (2023) · cites this paper as [60]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundSelf-citationSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationCongenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234 · cited 2×
“Clinicians measure biomarkers before and after dosing (42), and aim for 17OHP levels above the reference range and androstenedione within the reference range for good control, with normal 17OHP indicating overtreatment and high androstenedione indicating undertreatment (14, 24).”
BackgroundSelf-citationCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationCongenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628 · cited 1×
“Adrenal insufficiency causes life-threatening adrenal crises (1-3), while androgen excess causes atypical genitalia in 46,XX neonates, promotes abnormal growth, short stature, and precocious puberty, and in adulthood, virilization of women and infertility in both sexes (4).”
BackgroundSelf-citationHealth status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506 · cited 10×
“Current glucocorticoids used in the treatment of 21-OHD-CAH are immediate-release preparations such as hydrocortisone, prednisolone, prednisone, and dexamethasone, which fail to mimic the early-morning cortisol rise (10, 11).”
BackgroundMethodResultInfluentialSelf-citationCongenital Adrenal Hyperplasia: Is there an Effect on Penile Growth?
Levy, J. B., & Husmann, D. A. (1996) · The Journal of Urology · doi:10.1097/00005392-199608001-00060 · Cited by 415
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341 · cited 3×
“Management involves balancing glucocorticoid doses to avoid both glucocorticoid deficiency, risking adrenal crisis, and iatrogenic glucocorticoid excess, leading to short stature, obesity, hypertension, osteoporosis and an adverse metabolic profile (1-3,5-7).”
BackgroundSelf-citationModified-release hydrocortisone to provide circadian cortisol profiles
Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M. J., Newell-Price, J., Darzy, K., Merke, D. P., Arlt, W., & Ross, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2380 · Cited by 322 · cited 1×
“Cortisol has a circadian rhythm with a nadir on going to sleep, increasing during early morning hours, peaking on waking, then decreasing through the day (13).”
BackgroundSelf-citationFilipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundClinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313 · cited 9×
“This median dose is 20 to 40% less (5 to 10mg a day less) than that reported in the cohort studies (10,11,29,30).”
BackgroundMethodResultInfluentialSelf-citationPW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Self-citationRushworth, R. L., Torpy, D. J., & Falhammar, H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1807486 · Cited by 262 · cited 2×
“Management involves balancing glucocorticoid doses to avoid both glucocorticoid deficiency, risking adrenal crisis, and iatrogenic glucocorticoid excess, leading to short stature, obesity, hypertension, osteoporosis, and an adverse metabolic profile (1-3, 5-7).”
BackgroundExtensive expertise in endocrinology: adrenal crisis
Allolio, B. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0824 · Cited by 251
Plat, L., Leproult, R., L’Hermite-Baleriaux, M., Fery, F., Mockel, J., Polonsky, K. S., & Van Cauter, E. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.5978 · Cited by 225 · cited 3×
“Higher bedtime doses (reverse circadian regimen) are commonly used in an attempt to improve androgen control (11, 26, 27), with 84% at baseline in this study; however, evening glucocorticoid administration has the potential for adverse metabolic actions (28) and insomnia.”
MethodIncreased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Falhammar, H., Frisén, L., Norrby, C., Hirschberg, A. L., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2957 · Cited by 196 · cited 1×
“Patients with 21-OHD-CAH have increased mortality (8, 9) and poor health outcomes (10, 11) because current therapy fails to control adrenal androgen excess resulting in glucocorticoid overtreatment (5, 12).”
BackgroundCasteràs, A., De Silva, P., Rumsby, G., & Conway, G. S. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03563.x · Cited by 190
Sherlock, M., Reulen, R. C., Alonso, A. A., Ayuk, J., Clayton, R. N., Sheppard, M. C., Hawkins, M. M., Bates, A. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1097 · Cited by 185 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
Plat, L. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.9.3082 · Cited by 177
Mallappa, A., Sinaii, N., Kumar, P., Whitaker, M. J., Daley, L.-A., Digweed, D., Eckland, D. J. A., Van Ryzin, C., Nieman, L. K., Arlt, W., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3809 · Cited by 167 · cited 4×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundInfluentialSelf-citationBleicken, B., Hahner, S., Loeffler, M., Ventz, M., Decker, O., Allolio, B., & Quinkler, M. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03596.x · Cited by 148 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., et al. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00262 · Cited by 141 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundSelf-citationFrequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency
Reisch, N., Willige, M., Kohn, D., Schwarz, H.-P., Allolio, B., Reincke, M., Quinkler, M., Hahner, S., & Beuschlein, F. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0161 · Cited by 136 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
ResultSelf-citationApproach to the Adult with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Merke, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2417 · Cited by 132 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundSelf-citationTamhane, S., Rodriguez-Gutierrez, R., Iqbal, A. M., Prokop, L. J., Bancos, I., Speiser, P. W., & Murad, M. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01862 · Cited by 123 · cited 1×
“Management involves balancing glucocorticoid doses to avoid both glucocorticoid deficiency, risking adrenal crisis, and iatrogenic glucocorticoid excess, leading to short stature, obesity, hypertension, osteoporosis, and an adverse metabolic profile (1-3, 5-7).”
BackgroundWhitaker, M. J., Debono, M., Huatan, H., Merke, D. P., Arlt, W., & Ross, R. J. (2014) · Clinical Endocrinology · doi:10.1111/cen.12316 · Cited by 121 · cited 1×
“A modified-release formulation of hydrocortisone (MR-HC), with a delayedrelease action, given twice daily, simulates the overnight increase of cortisol (18, 19), and improved 21-OHD-CAH disease control in a phase 2 study (19).”
BackgroundSelf-citationApproach to the patient: the adult with congenital adrenal hyperplasia
Auchus, R. J., & Arlt, W. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1440 · Cited by 121 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundSelf-citationThe use of adrenalectomy as a treatment for congenital adrenal hyperplasia
Van Wyk, J. J. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.9.3180 · Cited by 119
Bouvattier, C., Esterle, L., Renoult-Pierre, P., de la Perrière, A. B., Illouz, F., Kerlan, V., Pascal-Vigneron, V., Drui, D., Christin-Maitre, S., Galland, F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4124 · Cited by 116
Self-citationTreatment and health outcomes in adults with congenital adrenal hyperplasia
Han, T. S., Walker, B. R., Arlt, W., & Ross, R. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.239 · Cited by 102 · cited 3×
“Patients with 21-OHD-CAH have increased mortality (8, 9) and poor health outcomes (10, 11) because current therapy fails to control adrenal androgen excess resulting in glucocorticoid overtreatment (5, 12).”
BackgroundSelf-citationFalhammar, H., Butwicka, A., Landén, M., Lichtenstein, P., Nordenskjöld, A., Nordenström, A., & Frisén, L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3707 · Cited by 98 · cited 1×
“Similarly higher replacement doses of hydrocortisone have been associated with lower quality of life (QoL) in patients with adrenal insufficiency (40), and lower psychological wellbeing (41).”
BackgroundMerza, Z., Rostami‐Hodjegan, A., Memmott, A., Doane, A., Ibbotson, V., Newell‐Price, J., Tucker, G. T., & Ross, R. J. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02544.x · Cited by 98 · cited 1×
“Hydrocortisone infusions mimicking the cortisol circadian rhythm have demonstrated improved biochemical control of 21-OHD-CAH (16, 17).”
MethodSelf-citationEl-Maouche, D., Hargreaves, C. J., Sinaii, N., Mallappa, A., Veeraraghavan, P., & Merke, D. P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00208 · Cited by 93 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundResultSelf-citationNella, A. A., Mallappa, A., Perritt, A. F., Gounden, V., Kumar, P., Sinaii, N., Daley, L.-A., Ling, A., Liu, C.-Y., Soldin, S. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1916 · Cited by 91 · cited 2×
“QoL has been shown to improve when using a pump to deliver subcutaneous diurnal hydrocortisone infusion to 21-OHD-CAH patients with poor control and QoL at baseline (17); however, QoL in 21-OHD-CAH has variably been reported as either impaired or normal (44).”
BackgroundMethodSelf-citationChakhtoura, Z., Bachelot, A., Samara-Boustani, D., Ruiz, J.-C., Donadille, B., Dulon, J., Christin-Maître, S., Bouvattier, C., Raux-Demay, M.-C., Bouchard, P., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0887 · Cited by 90
Self-citationWhittle, E., & Falhammar, H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00136 · Cited by 87 · cited 2×
“Patients often take glucocorticoids later in the evening to achieve biochemical control, when cortisol is normally low, resulting in metabolically adverse consequences (15).”
BackgroundJenkins-Jones, S., Parviainen, L., Porter, J., Withe, M., Whitaker, M. J., Holden, S. E., Morgan, C. L., Currie, C. J., & Ross, R. J. M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0895 · Cited by 85 · cited 1×
“Patients with 21-OHD-CAH have increased mortality (8, 9) and poor health outcomes (10, 11) because current therapy fails to control adrenal androgen excess resulting in glucocorticoid overtreatment (5, 12).”
BackgroundSelf-citationCongenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Flier, J. S., Underhill, L. H., Cutler, G. B., & Laue, L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199012273232605 · Cited by 83 · cited 2×
“Management involves balancing glucocorticoid doses to avoid both glucocorticoid deficiency, risking adrenal crisis, and iatrogenic glucocorticoid excess, leading to short stature, obesity, hypertension, osteoporosis and an adverse metabolic profile (1-3,5-7).”
BackgroundHan, T. S., Krone, N., Willis, D. S., Conway, G. S., Hahner, S., Rees, D. A., Stimson, R. H., Walker, B. R., Arlt, W., Ross, R. J., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0128 · Cited by 79
Self-citationFanelli, F., Gambineri, A., Belluomo, I., Repaci, A., Di Lallo, V. D., Di Dalmazi, G., Mezzullo, M., Prontera, O., Cuomo, G., Zanotti, L., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1381 · Cited by 69 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67) Female sex, No.”
BackgroundIncreased Infection Risk in Addison’s Disease and Congenital Adrenal Hyperplasia
Tresoldi, A. S., Sumilo, D., Perrins, M., Toulis, K. A., Prete, A., Reddy, N., Wass, J. A. H., Arlt, W., & Nirantharakumar, K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz006 · Cited by 65
Self-citationAdrenal Crises in Children: Perspectives and Research Directions
Rushworth, R. L., Torpy, D. J., Stratakis, C. A., & Falhammar, H. (2018) · Hormone Research in Paediatrics · doi:10.1159/000481660 · Cited by 60 · cited 2×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
Impact of Hydrocortisone on Adult Height in Congenital Adrenal Hyperplasia—The Minnesota Cohort
Sarafoglou, K., Addo, O. Y., Turcotte, L. M., Otten, N., Wickremasinghe, A. C., Pittock, S. T., Kyllo, J. H., Lteif, A. N., Himes, J. H., & Miller, B. S. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.01.011 · Cited by 57
Debono, M., Mallappa, A., Gounden, V., Nella, A. A., Harrison, R. F., Crutchfield, C. A., Backlund, P. S., Soldin, S. J., Ross, R. J., & Merke, D. P. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0064 · Cited by 53 · cited 2×
“In 21-OHD-CAH, the physiological pathway to androstenedione biosynthesis from 17hydroxypregenolone via DHEA is downregulated (43,44), and androstenedione biosynthesis primarily occurs through conversion of excess 17OHP.”
BackgroundSelf-citationPaizoni, L., Auer, M. K., Schmidt, H., Hübner, A., Bidlingmaier, M., & Reisch, N. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105540 · Cited by 53 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundSelf-citationIs physiological glucocorticoid replacement important in children?
Porter, J., Blair, J., & Ross, R. J. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-309538 · Cited by 50 · cited 2×
“MR-HC given twice daily replicates both the early morning increase in cortisol as well as daytime cortisol levels (22).”
BackgroundSelf-citationAdrenal crises in children with adrenal insufficiency: epidemiology and risk factors
Eyal, O., Levin, Y., Oren, A., Zung, A., Rachmiel, M., Landau, Z., Schachter‐Davidov, A., Segev‐Becker, A., & Weintrob, N. (2019) · European Journal of Pediatrics · doi:10.1007/s00431-019-03348-1 · Cited by 47 · cited 2×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
Pijnenburg-Kleizen, K. J., Thomas, C. M. G., Otten, B. J., Roeleveld, N., & der Grinten, H. L. C. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0006 · Cited by 35 · cited 3×
“Higher bedtime doses (reverse circadian regimen) are commonly used in an attempt to improve androgen control (11, 26, 27), with 84% at baseline in this study; however, evening glucocorticoid administration has the potential for adverse metabolic actions (28) and insomnia.”
MethodGhizzoni, L., Bernasconi, S., Virdis, R., Vottero, A., Ziveri, M., Volta, C., Iughetti, L., & Giovannelli, G. (1994) · Metabolism · doi:10.1016/0026-0495(94)90107-4 · Cited by 20 · cited 3×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67) Female sex, No.”
BackgroundManagement of the Adult with Congenital Adrenal Hyperplasia
Auchus, R. J. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/614107 · Cited by 17 · cited 3×
“Higher bedtime doses (reverse circadian regimen) are commonly used in an attempt to improve androgen control (11, 26, 27), with 84% at baseline in this study; however, evening glucocorticoid administration has the potential for adverse metabolic actions (28) and insomnia.”
MethodMelin, J., Hartung, N., Parra‐Guillen, Z. P., Whitaker, M. J., Ross, R. J., & Kloft, C. (2019) · Clinical Endocrinology · doi:10.1111/cen.13969 · Cited by 15 · cited 2×
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundSelf-citationTreatment of congenital adrenal hyperplasia.
Migeon, C. J. (1966) · PubMed · Cited by 9
Metabolic evaluation of young women with congenital adrenal hyperplasia
Schnaider, G. S., de Lemos‐Marini, S. H. V., Baptista, M. T. M., Guerra‐Júnior, G., Morcillo, A. M., de Mello, M. P., de Oliveira, L. C., & D’Souza-Li, L. F. R. (2011) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302011000800021 · Cited by 7 · cited 5×
“This median dose is 20% to 40% less (5-10 mg/day less) than that reported in the cohort studies (10, 11, 29, 30).”
BackgroundResultInfluential
Cited by
Congenital adrenal hyperplasia
Auer, M. K., Nordenström, A., Lajic, S., & Reisch, N. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01330-7 · Cited by 215
Self-citationTreating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“…(morning biochemical control of 17OHP and androstenedione), reduction in total daily dose and patients’ reported outcomes, the phase 3 study (559) failed to meet its primary endpoint (change from baseline to 24 weeks in the mean of the 24-hour 17OHP), probably for the prespecified methods…”
BackgroundManagement challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Self-citationPhase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
Auchus, R. J., Hamidi, O., Pivonello, R., Bancos, I., Russo, G., Witchel, S. F., Isidori, A. M., Rodien, P., Srirangalingam, U., Kiefer, F. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404656 · Cited by 79
“Additional approaches to GC-sparing therapy in classic CAH include subcutaneous or modified-release hydrocortisone 37,38 and flutamide plus testolactone 39 or abiraterone acetate 40,41 with physiological hydrocortisone.”
Self-citationDisorders of Sex Development of Adrenal Origin
Finkielstain, G. P., Vieites, A., Bergadá, I., & Rey, R. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.770782 · Cited by 67
“Made of uniform multiparticulate beads with an inert core, a hydrocortisone drug layer and a delayed release enteric outer coat, it aims to mimic the cortisol circadian rhythm and control the overnight ACTH surge that leads to the increase androgens (75, 77, 78).”
Background
Metadata
- Authors
- Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., Reisch, N., Stikkelbroeck, N., Touraine, P., Maltby, K., Treasure, F. P., Porter, J., & Ross, R. J.
- Affiliations
- National Institutes of Health (US)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Hospices Civils de Lyon, Fédération d’Endocrinologie, Groupement hospitalier Est, Bron Cedex, France
- Department of Women’s and Children’s Health, Karolinska Institutet and Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
- University of Copenhagen (DK)
- University of Sheffield (GB)
- Queen Elizabeth University Hospital (GB)
- Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK
- LMU Klinikum (DE)
- Radboud University Medical Center (NL)
- Sorbonne Université (FR)
- Diurnal (United Kingdom) (GB)
- Peter Treasure Statistical Services Ltd, Kings Lynn, UK
- Corresponding author
- Ross, Richard J
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-01-29
- Volume
- 106
- Issue
- 5
- Pages
- e2063-e2077
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC8063257
- OpenAlex
- W3127984913
- Semantic Scholar
- dcde4ff42d185ac53e64ec1c8c5ba43821258255
- Cited by
- 109
- References
- 56
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 23 · 2023: 18 · 2022: 13 · 2021: 8
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Yearbook of pediatric endocrinology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, modified-release hydrocortisone, glucocorticoid therapy, hyperandrogenism, 17-hydroxyprogesterone, adrenal crisis, dose reduction, pregnancy, patient-reported outcomes
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adult, Aged, Anti-Inflammatory Agents, Female, Follow-Up Studies, Humans, Hydrocortisone, Male, Middle Aged, Prognosis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.